ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biogen will spin off its hemophilia business to shareholders as an independent, publicly traded company and focus its efforts on developing drugs for neurodegenerative diseases. The new company, as yet unnamed, will pursue discovery and development of therapies for the treatment of hemophilia and market Biogen’s two existing drugs in that category, Eloctate and Alprolix, treatments for hemophilia A and hemophilia B, respectively. These two hemophilia drugs had $640 million in combined revenues during the 12-month period that ended on March 31. John G. Cox, Biogen’s current executive vice president of pharmaceutical operations and technology, will serve as CEO of the new company, which will be located in the Boston area. The spin-off is expected to be completed by early next year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X